ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hilgenberg, A. D.
Right arrow Articles by Grillo, H. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hilgenberg, A. D.
Right arrow Articles by Grillo, H. C.

The Annals of Thoracic Surgery, Vol 45, 357-363, Copyright © 1988 by The Society of Thoracic Surgeons

ARTICLES

Preoperative chemotherapy, surgical resection, and selective postoperative therapy for squamous cell carcinoma of the esophagus

AD Hilgenberg, RW Carey, EW Wilkins Jr, NC Choi, DJ Mathisen and HC Grillo
Surgical Services, Massachusetts General Hospital, Boston 02114.

In an attempt to improve on the long-term survival rate of patients with esophageal squamous cell carcinoma, we designed a study in which treatment included preoperative chemotherapy with fluorouracil and cisplatin, surgical resection, and selective postoperative chemotherapy or radiation therapy. Between 1981 and 1986, 35 patients with potentially resectable lesions were entered into the study. After chemotherapy, 13 of 35 patients (37%) had a complete clinical response, 7 (20%) had a partial response, and 15 (43%) had no response. One patient sustained a serious toxic reaction (renal failure). Twenty- seven patients underwent surgical resection, with 1 hospital death (3.7%). Selective postoperative radiotherapy or chemotherapy was administered to 69%. The actuarial survival of all resected patients at 42 months was 54% (standard error, 10%). Multivariate analysis showed significant factors associated with 3-year survival were: (1) complete clinical response to chemotherapy; (2) absence of wall penetration in the specimen; and (3) microscopic or no disease in the specimen. We conclude that this multimodality treatment method improves the intermediate-term survival of patients with squamous cell carcinoma of the esophagus.


This article has been cited by other articles:


Home page
 The OncologistHome page
M. Koshy, N. Esiashvilli, J. C. Landry, C. R. Thomas Jr., and R. H. Matthews
Multiple Management Modalities in Esophageal Cancer: Combined Modality Management Approaches
Oncologist, April 1, 2004; 9(2): 147 - 159.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. B. Polee, H. W. Tilanus, F. A. L. M. Eskens, R. Hoekstra, M. E. L. Van der Burg, P. D. Siersema, G. Stoter, and A. Van der Gaast
Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus
Ann. Onc., August 1, 2003; 14(8): 1253 - 1257.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Hayashi, N. Ando, H. Watanabe, H. Ide, K. Nagai, N. Aoyama, W. Takiyama, K. Ishida, K. Isono, H. Makuuchi, et al.
Phase II Evaluation of Protracted Infusion of Cisplatin and 5-Fluorouracil in Advanced Squamous Cell Carcinoma of the Esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407)
Jpn. J. Clin. Oncol., September 1, 2001; 31(9): 419 - 423.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1988 by The Society of Thoracic Surgeons.